# Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

> **NCT03748303** · PHASE1 · TERMINATED · sponsor: **University of Arizona** · enrollment: 6 (actual)

## Conditions studied

- Alzheimer Dementia

## Interventions

- **DRUG:** Allopregnanolone

## Key facts

- **NCT ID:** NCT03748303
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-01
- **Primary completion:** 2022-12-21
- **Final completion:** 2022-12-21
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study interrupted by COVID-19 pandemic and could not be restarted at current location. Study investigators determined that relocating and continuing the study under its original scope was not feasible given preliminary results from IM injections.
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03748303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03748303, "Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03748303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*